TROFUSE-005
Start here
Merck and Kelun-Biotech have reported global phase 3 results for sacituzumab tirumotecan in patients with advanced or recurrent endometrial cancer whose disease progressed after immunotherapy. In the TroFuse-005/ENGOT-en23/GOG-3095 trial (NCT06132958), the drug delivered median overall survival of 19.0 months versus 12.1 months in the comparator arm. The results mark a readout from the ongoing Merck-Kelun-Biotech collaboration on this antibody-drug conjugate. Regulatory submissions and presentation of the full dataset have not yet been detailed in the available reporting.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickMerck/Kelun-Biotech Report Global Phase 3 TroFuse-005 Endometrial Cancer OS Data for Sacituzumab Tirumotecan: 19.0 vs 12.1 Months
Merck and Kelun-Biotech reported global phase 3 data for sacituzumab tirumotecan in advanced or recurrent endometrial cancer after immunotherapy, with overall survival of 19.0 months versus 12.1 months. The phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial (NCT06132958) evaluated the drug in this patient population.
Heat trend for this story
Heat now 20·Peak in the comparable set 23 (Oct 26 12:00)·Change over 24h in the comparable set +200%·Participants now 4
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.